FamiCord Group, the largest cord blood bank in Europe, and CelluGen Biotech, a biotech company headquartered in Gurgaon, India, have signed a letter of intent (LOI) to cooperate across a range of business activities. Dated April 25, 2019, the specifics of the LOI state that the companies will pursue cooperation within the “field of family cord blood banking of stem cells and the use of stem cells in experimental and standard therapies.” The companies may jointly develop ATMPs and drugs. [Read more…]
ExCellThera’s Cell Expansion Technology, ECT-001, Receives FDA RMAT Designation
MONTREAL, April 23, 2019 — ExCellThera Inc., an advanced clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, announced today that the U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to its lead technology, ECT-001, in the treatment of hematologic malignancies. The RMAT designation is based on strong data from Phase I/II clinical trials using ECT-001 to expand stem and immune cells for the treatment of blood cancers. [Read more…]
Talaris Therapeutics Receives RMAT, Raises $100M, Announces Promising Phase II Data for Kidney Transplant
Talaris Therapeutics’ RMAT and Promising Phase 2 Data of Cell Therapy for Living Donor Kidney Transplant Recipients
BOSTON & LOUISVILLE, Ky.–Apr 18, 2019–Talaris Therapeutics, Inc., formerly Regenerex, a privately held biotechnology company developing transformative cell therapies that have the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients, today announced full results of its Phase 2 trial of FCR001 in living donor kidney transplant (LDKT) recipients. The therapy’s strong durability of benefit and safety profile support the initiation of a Phase 3 clinical trial in LDKT later this year.
Dr Professor Eckhard Alt from Germany to Lecture at AAOSCP’s May 2019 Workshop
Dr. Prof. Alt is a Leading Authority on Stem Cells, Electrophysiology, and Interventional Cardiology.
On May 3-5, 2019, the American Academy of Stem Cell Physicians (AAOSCP) will host a Scientific Congress and Workshop, featuring Basic Science to Clinical Practice. The AAOSCP is honored to announce that the event will feature renowned lecturer Eckhard U. Alt, MD, PhD, Professor of Medicine at Technische Universität in Munich, Professor at Tulane University in New Orleans and Professor at University of Texas MD Anderson Cancer Center in Houston. Dr. Prof. Alt is a leading global authority on Stem Cells, Electrophysiology, and Interventional Cardiology, holding more than 650 patents on these subjects worldwide. [Read more…]
L7 Informatics, Data Management and Process Automation Solutions for Cell and Gene Therapy Companies
Headquartered in Austin, Texas, L7 Informatics, provides software and services that enable synchronized solutions for cell and gene therapy companies. Specifically, L7’s novel Enterprise Science Platform (ESP) is a scientific process and data management (SPDM) solution that enables life science and healthcare companies to connect people, processes, and systems. The company’s mission is to use this technology to accelerate discoveries and drive precision healthcare.
In this interview, Vasu Rangadass – President and CEO of L7 Informatics – and I explore the company’s origins, its unique ESP technology, future directions, and more. Enjoy! [Read more…]
- « Previous Page
- 1
- …
- 209
- 210
- 211
- 212
- 213
- …
- 334
- Next Page »